Hamdan Medical Journal (previously the Journal of Medical Sciences)
|Table of Contents|
Th-1, Th-2 cells and beyond
The proliferation and differentiation of naïve CD4+ T helper (Th) cells after antigenic stimulation leads to functionally distinct subsets with different roles in immune response: Th-1 and Th-2 cells. Th- 1 cells produce large quantities of Interferon γ (INF-γ) inducing cell mediated immune responses against intracellular pathogens whereas Th-2 cells produce Interleukin (IL) 4, IL-5 and IL-13 which mediate humoral immunity eliminating extracellular pathogens and parasites.
Cite this article (Note that the Hamdan Medical Journal was previously called the Journal of Medical Sciences):
Lukik, ML. Th-1, Th-2 cells and beyond. Journal of Medical Sciences, 2008; 1(1): 5-7. DOI: http://dx.doi.org/10.2174/1996327000801010005
Mosmann TR., Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol, 1989; 7: 145 –173.
Romagnani S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 1992; 98: 279–285.
Simpson E. Special regulatory T-cell review: Regulation of immune responses-examining the role of T cells. Immunology, 2008;123: 13–16.
Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th17 axis: therapeutic targets of autoimmune. Current Opinion in Immunology, 2006; 18: 670-675.
Neufert C, Becker C, Wirtz S, Fantini MC, Weigmann B, Galle PR, et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol, 2007; 37: 1809–1816.
Kang BY, Kim TS. Targeting Cytokines of the Interleukin-12 Family in Autoimmunity. Current Medicinal Chemistry, 2006; 13: 1149–1156.
Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med, 2006; 203: 2785–2791.
Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nature Immunology, 2007; 8: 345–350.
Kimura A, Naka T, Kishimoto T. IL-6-dependent and – independent pathways in the development of interleukin 17-producing T helpher cells. National Academy of sciences, 2007;104: 12099–12104.
Nakes S, Nambu, A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol, 2003; 171: 6173–6177.
Lubberts E, Joosten LAB, Chabaud M, van den BersselaarL, van den Berg WB. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin
ligand and prevents bone erosion. J Clin Invest, 2000;105: 1697–1710.
Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB. Treatment with a neuralizing anti-murine inter leukin-17 antibody after the onset of collageninduced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum, 2001; 50: 168 – 177.
Lukic ML, Stosic-Grujicic S, Ostojic N, Chan WL, Liew FY. Inhibition of nitric oxide generation affects the induction of diabetes by streptozotocin in mice. Biochem Biophys Res Commun, 1991; 178: 913–920.
Miljkovic D, Cvetkovic I, Momcilovic M, Maksimovic- Ivanic D, Stosic-Grujicic S, Trajkovic V. Interleukin-17 stimulates inducible nitric oxide synthase-dependent
toxicity in mouse beta cells. Cell Mol Life Sci, 2005; 22: 2658–2668.
Mensah-Brown EP, Shahin A, Al-Shamsi M, Lukic ML. New members of the interleukin-12 family of cytokine and IL-27 modulate autoimmune diabetes. Ann N Y Acad Sci, 2006; 1079: 157–160.
Mensah-Brown EP, Shahin A, Al-Shamsi M, Wei X, Lukic, ML. IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin. Eur J Immunol, 2006; 36: 216–223.
Srinivasan S, Bolick DT, Lukashev D, Lappas C, Sitkovsky M, Lynch KR, et al. Sphingosine-1-Phosphate Reduces CD4+ T Lymphocyte Activation in Type 1 Diabetes through Regulation of Hypoxia-inducible Factor Short Isoform l.1 and CD69. Diabetes, 2007 Nov. 14 [Epub ahead of print].